EyePoint, Inc. (EYPT) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. My name is Antoine and I'll be your conference operator today. At this time, I would like to welcome everyone to the iPoint second quarter 2025 financial results and recent corporate developments conference call. There will be a question and answer session to follow the completion of the prepared remarks. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to George Elston, Executive Vice President and Chief Financial Officer of iPoint. Thank you, and thank you all for joining us on today's conference call to discuss iPoint's second quarter 2025 financial results and recent corporate developments. With me today is Dr. Jay Duker, President and Chief Executive Officer of iPoint. Jay will begin with a review of recent corporate updates and discuss the ongoing clinical trials for Duravue and WED-AMD. I will close with commentary on the second quarter of 2025 financial results, and we will then open the call for your questions. Earlier this morning, we issued a press release detailing our financial results and recent corporate developments. A copy of the release can be found on the Investor Relations tab on the company website, www.ipointpharma.com. Before we begin our formal comments, I'll remind you that various remarks we will make today constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. These include statements about our future expectations, clinical developments, and regulatory matters and timelines, the potential success of our products and product candidates, financial projections, and our plans and prospects. Actual results may differ materially from those indicated by these forward-looking stat...